Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
3417 | 1913 | 40.2 | 88% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CXCR2 | Author keyword | 46 | 39% | 5% | 93 |
2 | CXCR1 | Author keyword | 15 | 35% | 2% | 35 |
3 | G31P | Author keyword | 9 | 83% | 0% | 5 |
4 | MGSA | Author keyword | 9 | 83% | 0% | 5 |
5 | IL 8 RECEPTOR | Author keyword | 8 | 60% | 0% | 9 |
6 | CXCR2 ANTAGONISTS | Author keyword | 8 | 100% | 0% | 5 |
7 | ELR CXC CHEMOKINES | Author keyword | 8 | 100% | 0% | 5 |
8 | INTERLEUKIN 8 RECEPTORS | Author keyword | 8 | 62% | 0% | 8 |
9 | GRO ALPHA | Author keyword | 7 | 33% | 1% | 18 |
10 | CXCL5 | Author keyword | 7 | 39% | 1% | 14 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CXCR2 | 46 | 39% | 5% | 93 | Search CXCR2 | Search CXCR2 |
2 | CXCR1 | 15 | 35% | 2% | 35 | Search CXCR1 | Search CXCR1 |
3 | G31P | 9 | 83% | 0% | 5 | Search G31P | Search G31P |
4 | MGSA | 9 | 83% | 0% | 5 | Search MGSA | Search MGSA |
5 | IL 8 RECEPTOR | 8 | 60% | 0% | 9 | Search IL+8+RECEPTOR | Search IL+8+RECEPTOR |
6 | CXCR2 ANTAGONISTS | 8 | 100% | 0% | 5 | Search CXCR2+ANTAGONISTS | Search CXCR2+ANTAGONISTS |
7 | ELR CXC CHEMOKINES | 8 | 100% | 0% | 5 | Search ELR+CXC+CHEMOKINES | Search ELR+CXC+CHEMOKINES |
8 | INTERLEUKIN 8 RECEPTORS | 8 | 62% | 0% | 8 | Search INTERLEUKIN+8+RECEPTORS | Search INTERLEUKIN+8+RECEPTORS |
9 | GRO ALPHA | 7 | 33% | 1% | 18 | Search GRO+ALPHA | Search GRO+ALPHA |
10 | CXCL5 | 7 | 39% | 1% | 14 | Search CXCL5 | Search CXCL5 |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | NEUTROPHIL CHEMOTACTIC FACTOR | 85 | 38% | 9% | 180 |
2 | GROWTH STIMULATORY ACTIVITY | 74 | 55% | 5% | 93 |
3 | HUMAN INTERLEUKIN 8 RECEPTOR | 67 | 34% | 8% | 162 |
4 | IL 8 RECEPTOR | 48 | 49% | 4% | 70 |
5 | STIMULATORY ACTIVITY | 42 | 58% | 3% | 49 |
6 | IL 8 | 38 | 20% | 9% | 173 |
7 | FACTOR MDNCF | 35 | 89% | 1% | 16 |
8 | EPITHELIOID CELL LINE | 33 | 57% | 2% | 39 |
9 | NRK 52E | 25 | 73% | 1% | 19 |
10 | NEUTROPHIL ACTIVATING PEPTIDE | 22 | 51% | 2% | 31 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
INTERLEUKIN-8 AND RELATED CHEMOTACTIC CYTOKINES - CXC AND CC CHEMOKINES | 1994 | 1993 | 441 | 37% |
CXCR2 modulators: a patent review (2009-2013) | 2014 | 6 | 44 | 86% |
Interleukin-8 and human cancer biology | 2001 | 346 | 145 | 53% |
The functional significance behind expressing two IL-8 receptor types on PMN | 2009 | 90 | 156 | 48% |
Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells | 2013 | 14 | 98 | 55% |
Blockade of CXCR2 signalling: A potential therapeutic target for preventing neutrophil-mediated inflammatory diseases | 2014 | 6 | 88 | 52% |
CXCR2 Receptor Antagonists: A Medicinal Chemistry Perspective | 2014 | 3 | 101 | 77% |
PROPERTIES OF THE NOVEL PROINFLAMMATORY SUPERGENE INTERCRINE CYTOKINE FAMILY | 1991 | 1873 | 116 | 44% |
ESSENTIAL INVOLVEMENT OF INTERLEUKIN-8 (IL-8) IN ACUTE-INFLAMMATION | 1994 | 400 | 42 | 69% |
CXCR2 antagonists for the treatment of pulmonary disease | 2009 | 102 | 181 | 33% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | UNITE GENOME DIAGNOST IMMUNITAIRE VALORISAT | 2 | 67% | 0.1% | 2 |
2 | IMMUNOPHARMACOL BIOCHEM IMMUNOL | 1 | 100% | 0.1% | 2 |
3 | NEBRASKA MED 987660 | 1 | 50% | 0.1% | 2 |
4 | REGA MED IMMUNOBIOL | 1 | 100% | 0.1% | 2 |
5 | PIROL CRIT CARE SLEEP MED | 1 | 12% | 0.4% | 8 |
6 | AUTOIMMUN DIS | 1 | 50% | 0.1% | 1 |
7 | BIBS | 1 | 50% | 0.1% | 1 |
8 | BIOMOL UMR 7203 | 1 | 50% | 0.1% | 1 |
9 | BOAS MARKS | 1 | 50% | 0.1% | 1 |
10 | CHUKYO HOSP | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000213704 | LYMPHOTACTIN//CTAP III//CHEMOKINE STRUCTURE |
2 | 0.0000141248 | INTESTINAL EPITHELIAL//CRI 4U004B//LUMINAL CYTOKINES |
3 | 0.0000108639 | BB 10010//CK BETA 8//STEM CELL INHIBITOR |
4 | 0.0000101751 | EOTAXIN//CCR3//RANTES |
5 | 0.0000101305 | CCR2 ANTAGONIST//CCR2//CCR2 ANTAGONISTS |
6 | 0.0000096605 | DUFFY BLOOD GROUP//DARC//DUFFY ANTIGEN |
7 | 0.0000092680 | MONOCYTE CHEMOATTRACTANT PROTEIN 1//MCP 1 POLYMORPHISM//REGULATED UPON ACTIVATION |
8 | 0.0000088401 | CXCR3//CXCL10//CXCL9 |
9 | 0.0000081291 | EXPT LUNG//MACROPHAGE SECRETORY PRODUCTS//LUNG INFLAMMAT INFECT |
10 | 0.0000076062 | MNCF//NEUTROPHIL MIGRATION INHIBITION//NEUTROPHIL RECRUITMENT INHIBITORY FACTOR |